

INTRAPROSTATIC BOTULINUM TOXIN A ADMINISTRATION PRODUCES ANALGESIC AND ANTIINFLAMMATORY EFFECTS AGAINST CAPSAICIN INDUCED PROSTATITIS MODEL IN RATS

Hypothesis / aims of study

Chronic nonbacterial prostatitis is a commonly encountered clinical entity characterized by prostate pain in the absence of identifiable infection. Botulinum toxin type A (BoNT-A) has been claimed to inhibit nociceptive responses. Using a capsaicin-induced prostatitis model in rats, we evaluated the analgesic and anti-inflammatory properties of BoNT-A in the prostate.

Study design, materials and methods

Adult male S.D. rats (350-400gm weight) were injected with BoNT-A (5-20U) (Allergan, Irvine, CA) into the prostates followed by capsaicin (10 mM, 0.1 cc) injection to induce prostatitis after either 1 or 2 weeks. The nociceptive effects of capsaicin on the prostate were evaluated for 30 min by using a behavior approach and then the prostate was removed for histology by using H&E staining and for the change of cox-2 protein concentration by using western blotting.

Results

Capsaicin (10 mM, 0.1 cc) induced increase of painful behavior (eye movement, from 1.7 ± 0.2 to 4.2 ± 0.3 , vehicle vs capsaicin; locomotion, from 1.8 ± 0.3 to 4.5 ± 0.2 , vehicle vs capsaicin, $p < 0.001$; eyes movement: scoring 1 for normal opening, scoring 5 for complete closing; locomotion: scoring 1 for normal motion, scoring 5 for complete limpness of hindlimbs or motionless), which effects were significantly decreased by BoNT-A in a dose dependent fashion (eye movement, 3.0 ± 0.4 , 2.2 ± 0.3 , and 1.7 ± 0.3 for 5U, 10U, and 20U respectively; locomotion, 3.2 ± 0.4 , 2.8 ± 0.2 , 2.7 ± 0.2 for 5U, 10U, and 20U respectively.) Capsaicin induced increase of polymorphonuclear cells accumulation (PMN, from 29.2 ± 2.5 to 672.0 ± 81.5 , vehicle vs capsaicin, $p < 0.001$) and cox2 protein expression (30.3 ± 3.6 fold increase vs vehicle, $p < 0.001$), which effects were significantly decreased in BoNT-A 1 week pretreatment (PMN 434.0 ± 93.2 , 207.3 ± 54.8 , and 43.7 ± 3.9 for 5U, 10U, and 20U respectively; COX-2 expression 17.8 ± 1.7 fold, 9.2 ± 3.4 fold, and 3.2 ± 0.6 fold for 5U, 10U, and 20U respectively). The effects were decreased at two weeks pretreatment with BoNT-A.

Fig. 1 Western blot for detecting COX-2 expression. Protein amount of COX-2 was increased by capsaicin injection, which effect was decreased in BoNT-A treated animals in a dose dependent fashion.




Table 1. Effects of capsaicin (10 mM) and therapeutic effects of 5 U, 10 U, and 20 U BoNT-A on eye movement, locomotion, cell number of polymorphonuclear cells (PMN), and COX-2 expression one week before capsaicin injection.

	Eye	Locomotion	PMN number	COX-2
Vehicle	1.7 ± 0.2	1.8 ± 0.3	29.2 ± 2.5	1.0 ± 0.0
Capsaicin (Cap.)	4.2 ± 0.3	4.5 ± 0.2	672.0 ± 81.5	30.3 ± 3.6
5 U BoNT-A+Cap	3.0 ± 0.4	3.2 ± 0.4	434.0 ± 93.2	17.8 ± 1.7
10 U BoNT-A+CaP	2.2 ± 0.3	2.8 ± 0.2	207.3 ± 54.8	9.2 ± 3.4

20 U BoNT-A+CaP	1.7±0.3	2.7±0.2	43.7±3.9	3.2±0.6
-----------------	---------	---------	----------	---------

Data presented as means ± S. E.
N=6, for each group

Interpretation of results

BoNT-A can decrease polymorphonuclear cell accumulation, downregulate COX-2 expression and reduce prostate pain responses induced by capsaicin. BoNT-A injection into the prostate produced analgesic and anti-inflammatory effects on capsaicin induced prostatitis model in rats.

Concluding message

Intraprostatic BoNT-A injection could inhibit the capsaicin induced inflammatory change of prostate and reduce prostate pain. BoNT-A may be the potential drug to treat nonbacterial prostatitis in human.

FUNDING: Allergan and NSC-Taiwan

DISCLOSURES: NONE

ANIMAL SUBJECTS: This study followed the guidelines for care and use of laboratory animals and was approved by Chang Gung Memorial Hospital-Kaohsiung Medical Center